1887
Rapid communication Open Access
Like 0

Abstract

We followed 4,081,257 Australian adults aged ≥ 65 years between November 2022 and May 2023 for COVID-19-specific mortality, when recombinant SARS-CoV-2 Omicron lineages (predominantly XB and XBB) as well as BA.2.75 were circulating. Compared with a COVID-19 booster targeting ancestral SARS-CoV-2 given > 180 days earlier, the relative vaccine effectiveness against COVID-19 death of a bivalent (ancestral/BA.1 or ancestral/BA.4-5) booster given 8 to 90 days earlier was 66.0% (95%CI: 57.6 to 72.2%) and that of a monovalent ancestral booster given 8 to 90 days earlier was 44.7% (95%CI: 23.9 to 59.7%).

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.47.2300603
2023-11-23
2024-02-22
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2023.28.47.2300603
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/28/47/eurosurv-28-47-2.html?itemId=/content/10.2807/1560-7917.ES.2023.28.47.2300603&mimeType=html&fmt=ahah

References

  1. Department of Health and Aged Care. Communicable Diseases Intelligence, COVID-19 Australia: Epidemiology Report 77; 2023. Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/99424DA2A5F3A488CA2589BA0019141B/$File/covid_19_australia_epidemiology_report_77__reporting_period_ending_30_july_2023.pdf
  2. Liu B, Stepien S, Dobbins T, Gidding H, Henry D, Korda R, et al. Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study. Lancet Reg Health West Pac. 2023;40:100928.  https://doi.org/10.1016/j.lanwpc.2023.100928  PMID: 37854458 
  3. Pratt NL, Kerr M, Barratt JD, Kemp-Casey A, Kalisch Ellett LM, Ramsay E, et al. The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System. BMJ Open. 2018;8(4):e021122.  https://doi.org/10.1136/bmjopen-2017-021122  PMID: 29654048 
  4. Meindl B, Enderle T. cellKey -consistent perturbation of statistical tables. Conference of European Statisticians. 24 September 2019. Available from: https://unece.org/fileadmin/DAM/stats/documents/ece/ces/ge.46/2019/mtg1/SDC2019_S7_Austria_and_Germany_cellKey_Meindl_AD.pdf
  5. Network AC-S. Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 4 update. 2023. Available from: https://www.kirby.unsw.edu.au/sites/default/files/documents/COVID19-Blood-Donor-Report-Round4-Nov-Dec-2022%5B1%5D.pdf
  6. Kirsebom FCM, Andrews N, Stowe J, Ramsay M, Lopez Bernal J. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study. Lancet Infect Dis. 2023;23(11):1235-43.  https://doi.org/10.1016/S1473-3099(23)00365-1  PMID: 37453440 
  7. Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study. BMJ. 2023;382:e075286.  https://doi.org/10.1136/bmj-2022-075286  PMID: 37491022 
  8. Lin DY, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, et al. Effectiveness of Bivalent Boosters against Severe Omicron Infection. N Engl J Med. 2023;388(8):764-6.  https://doi.org/10.1056/NEJMc2215471  PMID: 36734847 
  9. Auvigne V, Tamandjou Tchuem CR, Schaeffer J, Vaux S, Parent Du Chatelet I. Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines - A matched cohort study in France. Vaccine. 2023;41(38):5490-3.  https://doi.org/10.1016/j.vaccine.2023.07.071  PMID: 37541823 
  10. Department of Health and Aged Care. ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.4/5) COVID-19 vaccine. 2023. Available from: https://www.health.gov.au/news/atagi-recommendations-on-use-of-the-pfizer-bivalent-originalomicron-ba45-covid-19-vaccine#:~:text=ATAGI%20advises%20that%20the%20Pfizer,the%20ATAGI%202023%20booster%20advice
  11. Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023;23(5):556-67.  https://doi.org/10.1016/S1473-3099(22)00801-5  PMID: 36681084 
  12. Gidding HF, Stepien S, Qian J, Macartney KK, Liu B. COVID-19 Vaccine Uptake by Infection Status in New South Wales, Australia. Emerg Infect Dis. 2023;29(5):1070-3.  https://doi.org/10.3201/eid2905.230047  PMID: 37015284 
  13. World Health Organization (WHO). Statement on the antigen composition of COVID-19 vaccines. Geneva: WHO;2023. Available from: https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines
/content/10.2807/1560-7917.ES.2023.28.47.2300603
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error